John Lechleiter - 2010 CEO Pay

John Lechleiter - Eli Lilly

Total Compensation: $16.5 million

Details: John Lechleiter received total compensation of $16.5 million last year, down 21 percent from 2009, when he snagged $20.9 million. While his salary actually increased slightly to $1.5 million (up from $1.48 million), his stock awards dropped to $8.175 million from $11.25 million.

Eli Lilly is facing a few challenging years ahead, but it managed to grow sales during the first quarter. The company's revenue increased by 6 percent on higher sales of several of its key drugs. And thanks to the weaker U.S. dollar, Lilly boosted its sales forecast for the full year. However, profits fell by 15 percent on restructuring and other costs, to $1.06 billion, or 96 cents per share.

Eli Lilly is now basing its employee bonuses partly on advances in its drug research pipeline, as Dow Jones notes.

Eli Lilly News:
Lilly CEO: No need for megadeals, we have Japan
As Zyprexa rivals near, Lilly CEO waives raise again
Analysts press Lilly chief for new strategy
Lilly CEO: We can weather the storm
Lilly CEO targets animal health, emerging markets
John Lechleiter - 2009 CEO Pay

 

John Lechleiter - 2010 CEO Pay
Read more on

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.